Alpha Teknova, Inc. Provides Revenue Guidance for Fiscal Year Ending December 31, 2022
August 11, 2022 at 01:31 am IST
Share
Alpha Teknova, Inc. provided revenue guidance for fiscal year ending December 31, 2022. For the period, Company expects total revenue of $38 million to $42 million, which assumes approximately 13% growth at the mid-point of guidance, excluding Sample Transport revenue. Total revenue growth is expected to be driven by an approximately 10% increase in Lab Essentials and at least a 45% increase in Clinical Solutions.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
ALPHA TEKNOVA, INC. 
